Clinical Trial

Medical Imaging and Focused Ultrasound Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will investigate Harmonic Motion Imaging guided Focused Ultrasound (HMIgFUS) method for ablation and sonoporation monitoring of breast tumors. The aim of this study is to evaluate the efficacy of real-time guidance/monitoring and ablation/sonoporation method. The hypothesis behind this proposed study is that High Intensity Focused Ultrasound (HIFU) can be used to ablate tumor tissue, and microbubble-mediated Low Intensity Focused Ultrasound (LIFU) can be used to sonoporate tumor vasculature. The investigators of this study also hypothesize that HMI can be used to monitor HIFU ablation by measuring the changes in tissue stiffness that occur as a result of thermal ablation, guide LIFU sonoporation and HIFU ablation targeting stiff tumor tissue, and the HMI-monitored stiffness changes during ablation will correlate with post-treatment immune response. The ultimate goals of this study are: first, to assess whether these techniques can be used in the clinic in order to provide a well-monitored, noninvasive tumor ablation/sonoporation method for benign tumors and breast cancers, to minimize side effects due to invasiveness and enhance therapeutic effects of current methods; second, to make full use of the real-time monitoring capability of HMIgFUS for more precise, point-of-care treatment planning to ensure success of ablation/sonoporation and immune activation.
Protocol Amendment History 5 changes
critical Phase changed: not applicable -> Phase 1 2026-08-14
notable Enrollment increased: 36 -> 82 participants 2026-08-14
minor Trial arms changed: 1 -> 2 2026-08-14
notable Primary completion pushed: 2026-05 -> 2031-05 2026-08-14
minor Completion pushed: 2026-05 -> 2031-05 2026-08-14
Trial Details
NCT Number NCT05219695
Lead Sponsor Columbia University
Collaborators: National Cancer Institute (NCI)
Conditions Fibroadenoma, Breast Cancer Stage I
Enrollment 82 participants
Start Date 2022-01-19
Primary Completion 2031-05 (estimated)
Study Completion 2031-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-13